查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1601252

RNA 治疗市场：按技术、适应症和最终用户划分 - 全球预测 2025-2030

RNA Therapy Market by Technology (Enabled Technologies, Enabling Technologies), Indication (Cancer, Cardiovascular, Genetic Disorders), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

RNA治疗市场2023年估值为21.8亿美元，预计2024年将达26亿美元，复合年增长率为22.38%，预计到2030年将达到89.8亿美元。

RNA疗法是生物技术和製药行业的前沿领域，专注于利用RNA分子治疗各种疾病。这种创新方法包括RNA干扰(RNAi)、反义寡核苷酸 (ASO) 和传讯RNA(mRNA) 疗法，它们透过标靶和操纵遗传物质发挥作用。对 RNA 疗法的需求源于其治疗传统小分子和蛋白质治疗方法难以解决的疾病的潜力，包括需要精确基因校正的遗传疾病、癌症，预计将应用于罕见疾病。 RNA 疗法的最终用途和应用正在扩大，在药物发现、临床试验和个人化医疗方面进行了大量投资。关键的成长要素包括递送技术的进步、对 RNA 机制的更好理解以及有利的法律规范。 RNA 治疗市场的最新潜在创新机会在于改善递送系统、扩大治疗标靶以及开发具有成本效益的製造流程。透过专注于与学术机构和生物技术公司的伙伴关係和合作，可以进一步加速创新。然而，递送功效、免疫抗原性问题和高开发成本等挑战以及监管障碍和市场竞争是主要限制因素。成熟的创新领域包括基于奈米颗粒的递送系统以及探索新型 RNA 修饰技术以提高稳定性并最大限度地减少脱靶效应。由于基因组学和生物技术的快速发展，市场格局充满活力，并以研发活动频繁的竞争环境为特征。为了利用不断变化的机会，相关人员应强调多学科合作，整合人工智慧主导的药物发现，并投资可扩展的生产技术以提高市场渗透率。对于希望利用 RNA 疗法进步的光明未来的公司来说，解决这些因素至关重要。

主要市场统计
基准年[2023] 21.8亿美元
预测年份 [2024] 26亿美元
预测年份 [2030] 89.8亿美元
复合年增长率（%） 22.38%

市场动态：揭示快速发展的 RNA 治疗市场的关键市场洞察

RNA 治疗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 人们对 RNA 在疾病病理学中的作用有了越来越多的了解
    • 个人化医疗需求不断成长
    • 透过与製药公司的策略联盟促进新RNA疗法的开发
  • 市场限制因素
    • RNA 疗法开发过程相关的高成本
  • 市场机会
    • 政府和私人机构增加对研发活动的投资
    • 基于 RNA 的管道疗法的临床试验
  • 市场挑战
    • RNA分子的不稳定性质和严格的监管准则所带来的问题

波特五力：驾驭 RNA 治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 RNA 治疗市场的外部影响

外部宏观环境因素在塑造 RNA 治疗市场的绩效动态方面发挥关键作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解RNA治疗市场的竞争状况

RNA 治疗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位基质 RNA 治疗市场供应商绩效评估

FPNV定位矩阵是评估RNA治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 加深我们对 RNA 在疾病病理学中作用的理解
      • 个人化医疗需求不断成长
      • 透过与製药公司的策略联盟促进新药开发
    • 抑制因素
      • RNA 疗法开发过程相关的高成本
    • 机会
      • 政府和私人组织增加对研发活动的投资
      • 基于 RNA 的疗法的临床试验管道
    • 任务
      • RNA分子不稳定引起的问题和严格的监管指南
  • 市场区隔分析
    • 技术：对推动 RNA 治疗进步的技术的需求不断增长。
    • 适应症：RNA疗法在遗传和癌症疾病的广泛应用。
    • 最终用户：专注于推动诊断和药物开发的新发现的学术研究变得越来越重要。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境
  • 客户客製化

第六章 RNA 治疗市场：依技术分类

  • 使能技术
    • 抑制
    • 标籤
    • 线性扩增
    • 微阵列
    • 精製
    • 定量RT-PCR
  • 实行技术
    • RNA反义技术
      • 微型RNA
      • 小干扰RNA
    • RNA干扰技术

第七章 RNA 治疗市场（按适应症）

  • 癌症
  • 心血管
  • 遗传疾病
  • 感染疾病
  • 肾臟疾病
  • 代谢紊乱
  • 肿瘤学
  • 视网膜疾病

第八章 RNA 治疗市场：依最终使用者分类

  • 学术研究
  • 诊断
  • 药物发现与开发

第九章美洲RNA治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太RNA治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲的RNA治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • ADARx Pharmaceuticals 是下一代 RNA 疗法的领导者，宣布超额认购 2 亿美元 C 轮资金筹措
    • ReNAgade Therapeutics 斥资 3 亿美元进军 RNA 治疗领域
    • Esperovax 和 Gingo Bioworks 宣布合作开发基于环状 RNA 的疗法

公司名单

  • Arbutus Biopharma Corporation
  • NeuBase Therapeutics, Inc.
  • Moderna, Inc.
  • Arcturus Therapeutics Holdings Inc.
  • BioNTech SE
  • AstraZeneca PLC
  • Arrowhead Pharmaceuticals, Inc.
  • Nordic Nanovector ASA
  • MiNA Therapeutics Limited
  • Silence Therapeutics PLC
  • Eli Lilly and Company
  • Cartesian Therapeutics, Inc.
  • Novartis AG
  • Sirnaomics, Inc.
  • F. Hoffmann-La Roche AG
  • ProQR Therapeutics NV
  • Cenix BioScience GmbH
  • Nutcracker Therapeutics, Inc.
  • Laronde
  • Triplet Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Deep Genomics
  • Biogen Inc.
  • GSK PLC
  • Benitec Biopharma Limited
  • Sanofi SA
  • Novo Nordisk A/S
Product Code: MRR-0375F3EAA7E7

The RNA Therapy Market was valued at USD 2.18 billion in 2023, expected to reach USD 2.60 billion in 2024, and is projected to grow at a CAGR of 22.38%, to USD 8.98 billion by 2030.

RNA therapy represents a cutting-edge segment of the biotechnology and pharmaceutical industries, focusing on the use of RNA molecules to treat a variety of diseases. This innovative approach includes RNA interference (RNAi), antisense oligonucleotides (ASOs), and messenger RNA (mRNA) therapies, which operate by targeting and manipulating genetic material. The necessity of RNA therapies is driven by their potential to treat conditions that are difficult to address with traditional small molecule and protein-based therapies, offering promise for genetic disorders, cancer, and rare diseases where precise genetic correction is crucial. The application and end-use scope of RNA therapy are expanding, with significant investments in drug discovery, clinical trials, and personalized medicine. Key growth factors include advancements in delivery technologies, increasing understanding of RNA mechanisms, and favorable regulatory frameworks. The latest potential opportunities in RNA therapy market innovation lie in refining delivery systems, expanding therapeutic targets, and developing cost-effective manufacturing processes. A focus on partnerships and collaborations with academic institutions and biotech companies could further accelerate innovation. However, challenges such as delivery efficacy, immunogenicity issues, and high development costs pose significant limitations, alongside regulatory hurdles and market competition. Areas ripe for innovation include nanoparticle-based delivery systems and the exploration of novel RNA modification techniques to enhance stability and minimize off-target effects. Given the rapid pace of advancements in genomics and biotechnology, the RNA therapy market is dynamic, characterized by a competitive landscape with a high degree of research and development activity. To capitalize on the evolving opportunities, stakeholders should emphasize interdisciplinary collaboration, integrate AI-driven drug discovery, and invest in scalable production technologies to enhance market penetration. Addressing these factors will be crucial for businesses aiming to capitalize on the promising future of RNA therapeutic advancements.

KEY MARKET STATISTICS
Base Year [2023] USD 2.18 billion
Estimated Year [2024] USD 2.60 billion
Forecast Year [2030] USD 8.98 billion
CAGR (%) 22.38%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving RNA Therapy Market

The RNA Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing understanding of the role of RNA in disease pathology
    • Heightened demand for personalized medicine
    • Strategic alliances by pharmaceutical companies to foster novel RNA therapy development
  • Market Restraints
    • High costs associated with RNA therapy development processes
  • Market Opportunities
    • Increased investments by governments and private organizations in research and development activities
    • Pipelined clinical trials of RNA-based therapeutics
  • Market Challenges
    • Issues arising from the unstable nature of RNA molecules and stringent regulatory guidelines

Porter's Five Forces: A Strategic Tool for Navigating the RNA Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the RNA Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the RNA Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the RNA Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the RNA Therapy Market

A detailed market share analysis in the RNA Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the RNA Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the RNA Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the RNA Therapy Market, highlighting leading vendors and their innovative profiles. These include Arbutus Biopharma Corporation, NeuBase Therapeutics, Inc., Moderna, Inc., Arcturus Therapeutics Holdings Inc., BioNTech SE, AstraZeneca PLC, Arrowhead Pharmaceuticals, Inc., Nordic Nanovector ASA, MiNA Therapeutics Limited, Silence Therapeutics PLC, Eli Lilly and Company, Cartesian Therapeutics, Inc., Novartis AG, Sirnaomics, Inc., F. Hoffmann-La Roche AG, ProQR Therapeutics N.V., Cenix BioScience GmbH, Nutcracker Therapeutics, Inc., Laronde, Triplet Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Deep Genomics, Biogen Inc., GSK PLC, Benitec Biopharma Limited, Sanofi S.A., and Novo Nordisk A/S.

Market Segmentation & Coverage

This research report categorizes the RNA Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Enabled Technologies and Enabling Technologies. The Enabled Technologies is further studied across Inhibition, Labeling, Linear amplification, Microarrays, Purification, and qRT-PCR. The Enabling Technologies is further studied across RNA Antisense Technologies and RNA Interference Technologies. The RNA Antisense Technologies is further studied across MicroRNA and Small interfering RNA.
  • Based on Indication, market is studied across Cancer, Cardiovascular, Genetic Disorders, Infectious Diseases, Kidney Diseases, Metabolic Disorders, Oncology, and Retinal Diseases.
  • Based on End User, market is studied across Academic Research, Diagnostics, and Drug Discovery & Development.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing understanding of the role of RNA in disease pathology
      • 5.1.1.2. Heightened demand for personalized medicine
      • 5.1.1.3. Strategic alliances by pharmaceutical companies to foster novel RNA therapy development
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with RNA therapy development processes
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased investments by governments and private organizations in research and development activities
      • 5.1.3.2. Pipelined clinical trials of RNA-based therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Issues arising from the unstable nature of RNA molecules and stringent regulatory guidelines
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Growing demand for enabled technologies to elevate the advancements in RNA therapies.
    • 5.2.2. Indication: Widespread applications of RNA therapy in genetic and cancer diseases.
    • 5.2.3. End User: Growing emphasis on academic research focusing on novel discoveries that propel diagnostics and drug development.
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. RNA Therapy Market, by Technology

  • 6.1. Introduction
  • 6.2. Enabled Technologies
    • 6.2.1. Inhibition
    • 6.2.2. Labeling
    • 6.2.3. Linear amplification
    • 6.2.4. Microarrays
    • 6.2.5. Purification
    • 6.2.6. qRT-PCR
  • 6.3. Enabling Technologies
    • 6.3.1. RNA Antisense Technologies
      • 6.3.1.1. MicroRNA
      • 6.3.1.2. Small interfering RNA
    • 6.3.2. RNA Interference Technologies

7. RNA Therapy Market, by Indication

  • 7.1. Introduction
  • 7.2. Cancer
  • 7.3. Cardiovascular
  • 7.4. Genetic Disorders
  • 7.5. Infectious Diseases
  • 7.6. Kidney Diseases
  • 7.7. Metabolic Disorders
  • 7.8. Oncology
  • 7.9. Retinal Diseases

8. RNA Therapy Market, by End User

  • 8.1. Introduction
  • 8.2. Academic Research
  • 8.3. Diagnostics
  • 8.4. Drug Discovery & Development

9. Americas RNA Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific RNA Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa RNA Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed USD 200 Million Series C Financing
    • 12.3.2. ReNAgade Therapeutics enters RNA Therapy Arena with USD 300 million
    • 12.3.3. Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics

Companies Mentioned

  • 1. Arbutus Biopharma Corporation
  • 2. NeuBase Therapeutics, Inc.
  • 3. Moderna, Inc.
  • 4. Arcturus Therapeutics Holdings Inc.
  • 5. BioNTech SE
  • 6. AstraZeneca PLC
  • 7. Arrowhead Pharmaceuticals, Inc.
  • 8. Nordic Nanovector ASA
  • 9. MiNA Therapeutics Limited
  • 10. Silence Therapeutics PLC
  • 11. Eli Lilly and Company
  • 12. Cartesian Therapeutics, Inc.
  • 13. Novartis AG
  • 14. Sirnaomics, Inc.
  • 15. F. Hoffmann-La Roche AG
  • 16. ProQR Therapeutics N.V.
  • 17. Cenix BioScience GmbH
  • 18. Nutcracker Therapeutics, Inc.
  • 19. Laronde
  • 20. Triplet Therapeutics, Inc.
  • 21. Ionis Pharmaceuticals, Inc.
  • 22. Alnylam Pharmaceuticals, Inc.
  • 23. Deep Genomics
  • 24. Biogen Inc.
  • 25. GSK PLC
  • 26. Benitec Biopharma Limited
  • 27. Sanofi S.A.
  • 28. Novo Nordisk A/S

LIST OF FIGURES

  • FIGURE 1. RNA THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. RNA THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RNA THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. RNA THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. RNA THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RNA THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RNA THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RNA THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RNA THERAPY MARKET SIZE, BY INHIBITION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RNA THERAPY MARKET SIZE, BY LABELING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RNA THERAPY MARKET SIZE, BY LINEAR AMPLIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RNA THERAPY MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RNA THERAPY MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RNA THERAPY MARKET SIZE, BY QRT-PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RNA THERAPY MARKET SIZE, BY MICRORNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RNA THERAPY MARKET SIZE, BY RNA INTERFERENCE TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL RNA THERAPY MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL RNA THERAPY MARKET SIZE, BY KIDNEY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL RNA THERAPY MARKET SIZE, BY RETINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL RNA THERAPY MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL RNA THERAPY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL RNA THERAPY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. INDIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. MALAYSIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. PHILIPPINES RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SINGAPORE RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH KOREA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TAIWAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. THAILAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. VIETNAM RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. DENMARK RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. EGYPT RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. FINLAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. FRANCE RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. GERMANY RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. ISRAEL RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. ITALY RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 213. NIGERIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. NORWAY RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. POLAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. QATAR RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 237. RUSSIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 255. SPAIN RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 261. SWEDEN RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 273. TURKEY RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 286. RNA THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 287. RNA THERAPY MARKET, FPNV POSITIONING MATRIX, 2023